Mycobacterium Smegmatis Tuberculosis | OMICS International | Mycobacterial Diseases

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Mycobacterium Smegmatis Tuberculosis

Treatment of tuberculosis has become a challenge due to the rapid increase of multidrug and extensive drug resistant Mycobacterium tuberculosis. Medicinal plants might represent a possible source for new potent antibacterials to which pathogen strains are not resistant. In the current research, five Combretum plant species-Combretum imberbe, Combretum zeyheri, Combretum hereroense, Combretum elaeagnoides and Combretum platypetalum used in traditional medicine were exposed to susceptibility tests to determine the effects of drug accumulation in avirulent M. smegmatis and M. aurum. Tuberculosis (TB) has threatened humanity for thousands of years and remains one of the deadliest diseases on planet earth.TB is believed to be largely a disease of poverty, with the highest incidences occurring in Asia and Africa. Scholarly open access mycobacterial journals cite their sources using references or bibliographies. OMICS Group International has 700+ peer-reviewed journals and organizes 3000+ International Scientific Conferences worldwide.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on April, 2021